Prognostic and Therapeutic Significance of Circulating Tumor Cells in Patients with Lung Cancer

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2019 Dec 13

PMID 31828552

Citations 26

Authors

Meysam Yousefi

Parisa Ghaffari

Rahim Nosrati

Sadegh Dehghani

Arash Salmaninejad

Yousef Jafari Abarghan

Seyed H Ghaffari

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is the second most common cancer and the main cause of cancer-related mortality worldwide. In spite of various efforts that have been made to facilitate the early diagnosis of lung cancer, most patients are diagnosed when the disease is already in stage IV, which is generally associated with the occurrence of distant metastases and a poor survival. Moreover, a large proportion of these patients will relapse after treatment, heralding the need for the stratification of lung cancer patients in addition to identifying those who are at a higher risk of relapse and, thus, require alternative and/or additional therapies. Recently, circulating tumor cells (CTCs) have been considered as valuable markers for the early diagnosis, prognosis and risk stratification of cancer patients, and they have been found to be able to predict the survival of patients with various types of cancer, including lung cancer. Additionally, the characterization of CTCs has recently provided fascinating insights into the heterogeneity of tumors, which may be instrumental for the development of novel targeted therapies.

Conclusions: Here we review our current understanding of the significance of CTCs in lung cancer metastasis. We also discuss prominent studies reporting the utility of enumeration and characterization of CTCs in lung cancer patients as prognostic and pharmacodynamic biomarkers for those who are at a higher risk of metastasis and drug resistance.

Citing Articles

A novel prediction model for the prognosis of non-small cell lung cancer with clinical routine laboratory indicators: a machine learning approach.

Wang Y, Mei N, Zhou Z, Fang Y, Lin J, Zhao F BMC Med Inform Decis Mak. 2024; 24(1):344.

PMID: 39558294 PMC: 11575007. DOI: 10.1186/s12911-024-02753-3.

2D compounds with heterolayered architecture for infrared photodetectors.

Gu H, Zhang T, Wang Y, Zhou T, Chen H Chem Sci. 2024; .

PMID: 39328196 PMC: 11423492. DOI: 10.1039/d4sc03428g.

An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.

Salmaninejad A, Layeghi S, Falakian Z, Golestani S, Kobravi S, Talebi S Clin Exp Med. 2024; 24(1):156.

PMID: 39003350 PMC: 11246281. DOI: 10.1007/s10238-024-01417-w.

Linking EMT Status of Circulating Tumor Cells to Clinical Outcomes in Lung Cancer.

Huangfu Y, Guo J, Zhao Y, Cao X, Han L Cancer Manag Res. 2024; 16:325-336.

PMID: 38654718 PMC: 11036334. DOI: 10.2147/CMAR.S449777.

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation.

Ren F, Fei Q, Qiu K, Zhang Y, Zhang H, Sun L J Exp Clin Cancer Res. 2024; 43(1):96.

PMID: 38561776 PMC: 10985944. DOI: 10.1186/s13046-024-03026-7.

References

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Andergassen U, Kolbl A, Hutter S, Friese K, Jeschke U . Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers (Basel). 2013; 5(4):1212-20. PMC: 3875936. DOI: 10.3390/cancers5041212. View

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C . Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014; 510(7503):167-71. PMC: 4061398. DOI: 10.1038/nature13277. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Normanno N, Rossi A, Morabito A, Signoriello S, Bevilacqua S, Di Maio M . Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer. 2014; 85(2):314-9. DOI: 10.1016/j.lungcan.2014.05.002. View

Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View

Tibbe A, Miller M, Terstappen L . Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 2007; 71(3):154-62. DOI: 10.1002/cyto.a.20369. View

Sarioglu A, Aceto N, Kojic N, Donaldson M, Zeinali M, Hamza B . A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015; 12(7):685-91. PMC: 4490017. DOI: 10.1038/nmeth.3404. View

Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H . Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res. 2012; 20(2-3):131-7. DOI: 10.3727/096504012x13473664562583. View

10.

Pailler E, Oulhen M, Billiot F, Galland A, Auger N, Faugeroux V . Method for semi-automated microscopy of filtration-enriched circulating tumor cells. BMC Cancer. 2016; 16:477. PMC: 4946105. DOI: 10.1186/s12885-016-2461-4. View

11.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

12.

Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler T, Kohler J . Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One. 2014; 9(1):e85350. PMC: 3897440. DOI: 10.1371/journal.pone.0085350. View

13.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S . Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22):6980-6. DOI: 10.1158/1078-0432.CCR-09-1095. View

14.

Jiang J, Zhao H, Shu W, Tian J, Huang Y, Song Y . An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells. Sci Rep. 2017; 7:42612. PMC: 5309797. DOI: 10.1038/srep42612. View

15.

Gorges T, Stein A, Quidde J, Hauch S, Rock K, Riethdorf S . Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®. PLoS One. 2016; 11(5):e0155126. PMC: 4868337. DOI: 10.1371/journal.pone.0155126. View

16.

Zhou J, Kulasinghe A, Bogseth A, OByrne K, Punyadeera C, Papautsky I . Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsyst Nanoeng. 2019; 5:8. PMC: 6387977. DOI: 10.1038/s41378-019-0045-6. View

17.

Gabriel M, Rodriguez Calleja L, Chalopin A, Ory B, Heymann D . Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. Clin Chem. 2016; 62(4):571-81. DOI: 10.1373/clinchem.2015.249706. View

18.

Muller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E . Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012; 14(4):R118. PMC: 3680931. DOI: 10.1186/bcr3243. View

19.

Chen L, Peng M, Li N, Song Q, Yao Y, Xu B . Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer. Sci Rep. 2018; 8(1):1188. PMC: 5775318. DOI: 10.1038/s41598-018-19391-1. View

20.

Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures J . Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013; 59(9):1384-92. DOI: 10.1373/clinchem.2013.202846. View